This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Gilead Sciences Identifier:
First received: August 20, 2013
Last updated: February 10, 2017
Last verified: February 2017
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection.

Condition Intervention Phase
HBV Chronic HIV Infection Drug: TAF Drug: TDF Drug: TAF Placebo Drug: TDF Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B

Resource links provided by NLM:

Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL [ Time Frame: Week 48 ]
    The primary efficacy endpoint was determined by the achievement of HBV DNA < 29 IU/mL at Week 48.

Secondary Outcome Measures:
  • Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 [ Time Frame: Baseline; Week 48 ]
  • Percent Change From Baseline in Spine BMD at Week 48 [ Time Frame: Baseline; Week 48 ]
  • Change From Baseline in Serum Creatinine at Week 48 [ Time Frame: Baseline; Week 48 ]

Other Outcome Measures:
  • Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48 [ Time Frame: Up to 48 weeks ]
    Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method.

Enrollment: 426
Actual Study Start Date: September 2013
Estimated Study Completion Date: January 2024
Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TAF 25 mg
TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
Drug: TAF
25 mg tablet administered orally once daily
Other Names:
  • Vemlidy®
  • GS-7340
Drug: TDF Placebo
Tablet administered orally once daily
Active Comparator: TDF 300 mg
TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
Drug: TDF
300 mg tablet administered orally once daily
Other Name: Viread®
Drug: TAF Placebo
Tablet administered orally once daily
Experimental: Open-label TAF
All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.
Drug: TAF
25 mg tablet administered orally once daily
Other Names:
  • Vemlidy®
  • GS-7340

Detailed Description:
This study GS-US-320-0108 is an international study planned to enroll participants in global countries, including China. However, due to the review timeline difference in China, full enrollment was reached in the main study before China was able to participate. Therefore, details for the China cohorts were registered separately (NCT02836236) on as these cohorts will not be part of the main study analysis.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
  • Adult males and non-pregnant, non-lactating females
  • Documented evidence of chronic HBV infection
  • Hepatitis e antigen (HBeAg)-negative, chronic hepatitis B with all of the following:

    • HBeAg-negative and hepatitis B e antibody (HBeAb) positive at screening
    • Screening HBV DNA ≥ 2 x 10^4 IU/mL
    • Screening serum alanine aminotransferase (ALT) level > 60 U/L (males) or > 38 U/L (females) and ≤ 10 x the upper limit of the normal range (ULN)
  • Treatment-naive participants (defined as < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue), OR treatment-experienced participants (defined as participants meeting all entry criteria [including HBV DNA and serum ALT criteria] and with ≥ 12 weeks of previous treatment with any nucleoside or nucleotide analogue)
  • Previous treatment with interferon (pegylated or non pegylated) must have ended at least 6 months prior to the baseline visit.
  • Adequate renal function
  • Normal ECG

Key Exclusion Criteria:

  • Females who are breastfeeding
  • Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study
  • Co-infection with hepatitis C virus, HIV, or hepatitis D virus
  • Evidence of hepatocellular carcinoma
  • Any history of, or current evidence of, clinical hepatic decompensation
  • Abnormal hematological and biochemical parameters, including aspartate aminotransferase (AST) > 10 x ULN
  • Received solid organ or bone marrow transplant
  • History of malignancy within the past 5 years, with the exception of specific cancers that are cured by surgical resection; individuals under evaluation for possible malignancy are not eligible
  • Currently receiving therapy with immunomodulators (eg, corticosteroids), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion
  • Individuals receiving ongoing therapy with drugs not to be used with tenofovir alafenamide or tenofovir disoproxil fumarate or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients
  • Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01940341

  Hide Study Locations
United States, California
Asian Pacific Liver Center
Los Angeles, California, United States, 90057
Stanford University Medical Center
Palo Alto, California, United States, 94304
Huntington Medical Research Institutes
Pasadena, California, United States, 91105
Research and Education, Inc.
San Diego, California, United States, 92105
University California San Francisco (UCSF)
San Francisco, California, United States, 94110
Silicon Valley Research Institute
San Jose, California, United States, 95128
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, Maryland
Digestive Disease Associates, PA
Baltimore, Maryland, United States, 21229
United States, Michigan
Orlando Clinical
Detroit, Michigan, United States, 48202
United States, New Jersey
ID Care
Hillsborough, New Jersey, United States, 08844
United States, New York
Medical Procare, PLLC
Flushing, New York, United States, 11355
Sing Chan Private Practice
Flushing, New York, United States, 11355
United States, Pennsylvania
Xiaoli Ma, PC
Philadelphia, Pennsylvania, United States, 19107
United States, Virginia
Hunter Holmes McGuire VA DVMC
Richmond, Virginia, United States, 23249
Australia, Victoria
Monash Medical Centre
Clayton, Victoria, Australia, 3168
Western Hospital- Footscray Hospital
Footscray, Victoria, Australia, 3011
Austin Health
Heidelberg, Victoria, Australia, 3084
Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
Australia, Western Australia
Royal Perth Hospital
Perth, Western Australia, Australia, 6000
St. Vincent's Hospital
Fitzroy, Australia, 3065
Sir Charles Gairdner Hospital
Nedlands, Australia, 6009
Canada, Alberta
Heritage Medical Research Clinic
Calgary, Alberta, Canada, T2N 4Z6
University of Alberta
Edmonton, Alberta, Canada, T6G 2X8
Canada, British Columbia
Liver and Intestinal Research Centre
Vancouver, British Columbia, Canada, V5Z 1H2
University of British Columbia
Vancouver, British Columbia, Canada, V5Z 1M9
Dr. John Farley Inc.
Vancouver, British Columbia, Canada, V6A 4B6
Vancouver Infectious Disease Research and Care Centre
Vancouver, British Columbia, Canada, V6Z 2C7
Gastrointestinal Research Institute (GIRI)
Vancouver, British Columbia, Canada, V6Z 2K5
Canada, Manitoba
University of Manitoba, Health Science Center
Winnipeg, Manitoba, Canada, R3E 3P4
Canada, Ontario
University Health Network / Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Toronto Western Hospital
Toronto, Ontario, Canada, M5T 2S8
Toronto Liver Centre
Toronto, Ontario, Canada, M6H 3M1
China, Guangdong
Guangzhou No.8 People's Hospital
Guangzhou, Guangdong, China, 510060
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515
The Third Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China, 510630
China, Guangxi
The 1st Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China, 530021
China, Guizhou
The Affiliated Hospital of Guiyang Medical College
Guiyang, Guizhou, China, 500000
China, Hainan
The People's Hospital of Hainan Province
Haikou, Hainan, China, 570311
China, Hebei
The 3rd Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050051
China, Hubei
Tongji Hospital, Tongji Medical college HuaZhong University of Science&Technology
Wuhan, Hubei, China, 430030
China, Hunan
XiangYa Hospital Central South University
Changsha, Hunan, China, 410008
The 2nd Xiangya Hospital Central South University
Changsha, Hunan, China, 410011
China, Jiangsu
Nanjing No. 2 Hospital
Nanjing, Jiangsu, China, 210003
Jiangsu Provincial People' Hospital
Nanjing, Jiangsu, China, 210029
China, Jiangxi
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330000
China, Jilin
The First Hospital of Jilin University
Changchun, Jilin, China, 130021
China, Liaoning
The sixth People's Hospital of Shenyang
Shenyang, Liaoning, China, 110006
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110022
China, Shandong
Jinan Infectious Disease Hospital
Jinan, Shandong, China, 250021
China, Shanxi
First Affiliated Hospital of Xi'an Jiaotong
Xi'an, Shanxi, China, 710061
China, Sichuan
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610041
China, Yunnan
No.1 Hospital Affiliated to Kunming Medical College
Kunming, Yunnan, China, 650032
Beijing Ditan Hospital
Beijing, China, 100011
Peking University First Hospital
Beijing, China, 100034
Peking University People's Hospital
Beijing, China, 100044
Beijing Friendship Hospital, Capital Medical University
Beijing, China, 100050
Beijing You An Hospital,Capital Medical University
Beijing, China, 100069
No. 302 PLA Hospital
Beijing, China
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, China, 200025
85 Hospital of People's Liberation Army
Shanghai, China, 200052
Shanghai Public Health Clinical Center
Shanghai, China, 201508
Hopital Civil de Strasbourg
Strasbourg, Alsace, France, 67091
Hôpital de la Croix Rousse
Lyon, Rhône-Alpes, France, 69317
Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
Prince of Wales Hospital
Sha Tin, Hong Kong
Alice Ho Miu Ling Nethersole Hospital
Tai Po, Hong Kong
Global Hospitals
Hyderabad, Andhra Pradesh, India, 500004
Hyderabad, Andhra Pradesh, India, 500082
Institute of Liver Diseases, HPB Surgery and Transplant Global Hospitals
Parel, Maharashtra, India, 400012
Seth GS Medical College and KEM Hospital
Mumbai, Maharastra, India, 400012
Institute of Post Graduate Medical Education And Research
Kolkata, West Bengal, India, 700020
Postgraduate Institute of Medical Education and Research
Chandigarh, India, 160012
Centre for Liver Research & Diagnostic, Deccan College of Medical Sciences and Allied Hospitals
Hyderabad, India, 500058
S.R. Kalla Hospital
Jaipur, India, 302001
All India Institute of Medical Sciences
New Delhi, India, 110029
Institute of Liver and Biliary Sciences
New Delhi, India, 110070
Nirmal Hospital
Surat, India, 395002
Azienda Ospedaliera di Bologna - Policlinico S. Orsola Malpighi
Bologna, Italy, 40138
Azienda Ospedaliero Universitaria Pisana
Cisanello Pisa, Italy, 56124
Ospedali Riuniti Azienda Ospedaliera Universitaria di Foggia
Foggia, Italy, 71122
Casa Sollievodella Soferrenza IRCCS
San Giovanni Rotondo, Italy, 71013
Kyushu University Hospital Fukuoka
Fukuoka-shi, Japan, 812-8582
Shin-Kokura Hospital
Fukuoka, Japan, 803-8505
Kobe City Medical Center General Hospital
Hyogo, Japan, 650-0047
Kurume University Hospital
Kurume, Japan, 830-0011
Japan Red Cross Musashino Hospital
Musashino, Japan, 180-8610
Hyogo College of Medicine
Nishinomiya, Japan, 663-8501
National Hospital Organization Nagasaki Medical Center
Omura, Japan, 856-8562
Osaka Red Cross Hospital
Osaka, Japan, 543-8555
Hokkaido University Hospital
Sapporo, Japan, 060-8648
Osaka University Hospital
Suita, Japan, 565-0871
Medical Hospital of Tokyo Medical and Dental University
Tokyo, Japan, 113-8519
Korea, Republic of
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, Korea, Republic of
Keimyung University Dongsan Medical Center
Daegu, Korea, Republic of, 700-712
Kyungpook National University Hospital
Daegu, Korea, Republic of, 700-721
Gangnam-gu, Korea, Republic of, 135-720
Yonsei University, Severance Hospital
Seoul, Korea, Republic of, 120-752
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Seoul Saint Mary Hospital
Seoul, Korea, Republic of, 137-701
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Korea University Guro Hospital
Seoul, Korea, Republic of, 152-703
New Zealand
Auckland Clinical Studies Limited
Grafton, Auckland, New Zealand, 1142
Wojewodzki Szpital Specjalistyczny im Dluskeigo
Bialystok, Poland, 15-540
Szpital Specjalistyczny
Chorzow, Poland, 41-500
Oddziak Obserwacyjno-Zakazny
Lodz, Poland, 91-347
Klinika Chorob Zakaznych AM
Wroclaw, Poland, 50-349
Institutul National de Boli Infectioase Prof.Dr. Matei Bals
Bucharest, Bucuresti, Romania, 21105
Constanta Clinical Hosp. for Infectious Diseases (attn: Halikidis Stela, MD)
Constanta, Romania, 900708
Institutul de Gastroenterologie si Hepatologie lasi
Iasi, Romania, 700506
Russian Federation
Karaganda State Medical Institute
Koltsovo, Novosibirsk, Russian Federation, 630559
University Clinical Hospital #1
Moscow, Russian Federation, 119991
Limited Liability Company "Modern Medicine Clinic"
Moscow, Russian Federation, 121293
State fiscal health agency of Moscow "Infectious Clinical Hospital 1 Moscow Health Department"
Moscow, Russian Federation, 125367
State Budgetary Healthcare Institution "State Novosibirsk Regional Clinical Hospital"
Novosibirsk, Russian Federation, 630087
Novosobirsk State Medical University
Novosibirsk, Russian Federation, 630091
Institute of Clinical Immunology RAMS, Clinic of Immunopathology
Novosibirsk, Russian Federation, 630099
Municipal Clinical Hospital n.a. S.P. Botkin
Saint-Petersburg, Russian Federation, 191167
Federal State Budget Military Educational Institution Medical Military Academy n. a. S. M. Kirov
Saint-Petersburg, Russian Federation, 194044
Research Institute of Influenza
Saint-Petersburg, Russian Federation, 197376
Hospital Universitari Vall d'Hebron
Barcelona, Spain, 8035
Hualien Tzu Chi Medical Center
Hualien, Taiwan, 970
Kaohsiung Med. College Hosp. Dept. of Internal Medicine
Kaohsiung, Taiwan, 80756
Taichung Veterans General Hospital
Taichung, Taiwan, 40705
National Cheng Kung University Hospital
Tainan, Taiwan, 70428
National Taiwan University Hospital
Taipei, Taiwan, 10002
Dicle University Medical Faculty Department of Infectious Diseases
Diyarbakir, Diyarbakri, Turkey, 21280
Ankara University Medical Faculty Hospital
Ankara, Turkey, 6590
University of Uludag
Gorukle-Bursa, Turkey, 16059
Istanbul Universitesi Cerrahpassa Tip Fakultesi Hastanesi
Istanbul, Turkey, 34098
Ege Universitesi Tip Fakultesi Hastanesi
Izmir, Turkey, 35040
United Kingdom
Barts & The London NHS Trust
London, United Kingdom, E1 1BB
King's College Hospital
London, United Kingdom, SE5 9RS
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom, NG7 2UH
Sponsors and Collaborators
Gilead Sciences
Study Director: Gilead Study Director Gilead Sciences
  More Information

Responsible Party: Gilead Sciences Identifier: NCT01940341     History of Changes
Other Study ID Numbers: GS-US-320-0108
2013-000626-63 ( EudraCT Number )
Study First Received: August 20, 2013
Results First Received: December 9, 2016
Last Updated: February 10, 2017

Keywords provided by Gilead Sciences:

Additional relevant MeSH terms:
HIV Infections
Hepatitis B
Liver Diseases
Digestive System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Hepatitis, Viral, Human
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents processed this record on July 21, 2017